Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The stock is in a well-established, long-term rising trend above the technical support level at 88.71 USD
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 110.79.
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • The group usually releases earnings worse than estimated.
  • Based on current prices, the company has particularly high valuation levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 51.62 times its estimated earnings per share for the ongoing year.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart
Sector Medical Equipment, Supplies & Distribution - NEC
1st jan.Capitalisation (M$)Investor Rating
ABBOTT LABORATORIES22.80%188 845
MEDTRONIC PLC-4.97%144 920
BECTON, DICKINSON AND COMPA..-16.24%66 032
BAXTER INTERNATIONAL INC.-1.55%41 673
HOYA CORPORATION9.95%40 612
DEXCOM, INC.76.56%36 977
SARTORIUS STEDIM BIOTECH98.38%31 933
TERUMO CORPORATION8.03%30 374
ZIMMER BIOMET HOLDINGS-4.60%29 565
ALIGN TECHNOLOGY, INC.17.56%25 844
WEST PHARMACEUTICAL SERVICE..87.11%20 303
AMERISOURCEBERGEN CORPORATI..13.87%19 763
SYSMEX CORPORATION34.02%19 332
BIO-RAD LABORATORIES, INC.38.68%15 021
STERIS PLC11.64%14 587
AVANTOR, INC.23.91%12 968
More Results
Financials (USD)
Sales 2020 33 067 M - -
Net income 2020 3 667 M - -
Net Debt 2020 12 312 M - -
P/E ratio 2020 51,6x
Yield 2020 1,36%
Capitalization 189 B 189 B -
EV / Sales 2020 6,09x
EV / Sales 2021 5,32x
Nbr of Employees 107 000
Free-Float 88,8%
Upcoming event on ABBOTT LABORATORIES
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes